Modelling intestinal absorption of salbutamol sulphate in rats

International Journal of Pharmaceutics

Volumn 314, Issue 1, 2006, Pages 21-30

  Valenzuela, B ^a   Lopez Pintor E ^a   Perez Ruixo J J ^a,b   Nacher A ^c   Martin Villodre A ^c   Casabo V G ^c  

^a UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Active transport; Intestinal absorption; Kinetic modelling; Oral bioavailability; P glycoprotein inhibitors; Salbutamol sulphate

Indexed keywords

SALBUTAMOL SULFATE; SODIUM AZIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG POTENTIATION; DRUG TRANSPORT; GRAPEFRUIT JUICE; INTESTINE ABSORPTION; INTESTINE CELL; MALE; NONHUMAN; NONPARAMETRIC TEST; PARAMETRIC TEST; PRIORITY JOURNAL; PROCESS MODEL; RAT; VALIDATION STUDY;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANIMALS; BEVERAGES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CITRUS PARADISI; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; RATS; RATS, WISTAR; SODIUM AZIDE; VERAPAMIL;

EID: 33646529646     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.01.019     Document Type: Article

References (36)

1. Ahrens R.C., and Smith G.D. Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 4 (1984) 105-121
2. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
3. Beal, S.L., Boeckmann, A., Sheiner, L.B., 1988-1998. NONMEM users guides. Part I-VIII, NONMEM Project Group C2555. University of California at San Francisco, San Francisco.
4. Chiou W.L., and Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 21 (1998) 217-223
5. Dayneka N.L., Garg V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 (1993) 457-478
6. Doluisio J.T., Billups N.F., Dittert L.W., Sugita E.T., and Swintosky J.V. Drug absorption. Part I. An in situ rat gut technique yielding realistic absorption rates. J. Pharm. Sci. 56 (1969) 1196-1200
7. Edwards D.J., Bellevue III F.H., and Woster P.M. Identification of 6′,7′-dihidroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug. Metab. Dispos. 24 (1996) 1287-1290
8. Ehrhardt C., Kneuer C., Bies C., Lehr C.M., Kim K.J., and Bakowsky U. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm. Pharmacol. Ther. 18 (2005) 165-170
9. Efron B., and Tibshirani R. An Introduction to the Bootstrap (1993), Chapman & Hall, London, UK
10. Ette E.I. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37 (1997) 486-495
11. Fernandez-Teruel C., Gonzalez-Alvarez I., Casabo V.G., Ruiz-Garcia A., and Bermejo M. Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells. J. Drug Target 13 (2005) 199-212
12. Gabús-Sannié C., and Buri P. Étude comparative des méthodes de détermitation du volume d'eau absorbé lors de perfusion de l'íntestine grêle du rat. S.T.P. Pharma 3 (1987) 856-860
13. Katsura T., and Iuni K. Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokin. 18 (2003) 1-15
14. Leal N., Calvo R., Agrad F.Z., Lukas J.C., de la Fuente L., and Suarez E. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. J. Pharm. Pharmacol. 57 (2005) 317-325
15. Legen I., Žakelj S., and Kristl A. Polarised transport of monocarboxylic acid type drugs across rat jejunum in vitro: the effect of mucolysis and ATP-depletion. Int. J. Pharm. 256 (2003) 161-166
16. Lindstrom M.J., and Bates T.M. Nonlinear mixed effects models for repeated measures. Biometrics 46 (1990) 673-687
17. Martín-Villodre A., Plá-Delfina J.M., Moreno-Dalmau J., Pérez-Buendía M.D., Miralles J., Collado E., Sánchez-Moyano E., and Del Pozo A. Studies on the reliability of a bihyperbolic functional absorption model. Part I. Ring substituted anilines. J. Pharmacokinet. Biopharm. 14 (1986) 615-633
18. Muñoz M.J., Merino-Sanjuan M., Lledó-García R., Casabó V.G., Mañez-Castillejo F.J., and Nácher A. Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat. Eur. J. Pharm. Biopharm. 61 (2005) 20-26
19. Pacifici G.M., Giulianetti B., Quilici M.C., Spisni R., Nervi M., Giuliani L., and Gomeni R. (-)-salbutamol sulphate sulphation in the human liver and duodenal mucosa: interindividual variability. Xenobiotica 27 (1997) 279-286
20. Parker T.J., Della Pasqua O.E., Loizillon E., Chezaubernard C., Jochemsen R., and Danhof M. Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats. Br. J. Pharmacol. 132 (2001) 151-158
21. Rodríguez-Ibáñez M., Nalda-Molina R., Montalar-Montero M., Bermejo M.V., Merino V., and Garrigues T.M. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. Eur. J. Pharm. Biopharm. 55 (2003) 241-246
22. Ruíz-Balaguer N., Nácher A., Casabó V.G., and Merino M. Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats. Antimicrob. Agents Chemother. 41 (1997) 445-448
23. Ruíz-Balaguer N., Nácher A., Casabó V.G., and Merino-Sanjuán M. Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. Int. J. Pharm. 234 (2002) 101-111
24. Sánchez-Picó A., Peris-Ribera J.E., Toledano C., Torres-Molina F., Casabó V.G., Martín-Vilodre A., and Plá-Delfina J.M. Nonlinear intestinal absorption kinetics of cefadroxil in the rat. J. Pharm. Pharmacol. 41 (1989) 179-185
25. Sancho-Chust V., Bengoechea M., Fabra-Campos S., Casabó V.G., Martínez-Cámara M.J., and Martín-Villodre A. Experimental studies on the influence of surfactants on intestinal absorption of drugs. Cefadroxil as model drug and sodium laurylsulfate as model surfactant: studies in rat duodenum. Arzneimittelforschung 45 (1995) 1013-1017
26. Shono Y., Nishihara H., Matsuda Y., Furukawa S., Okada N., Fujita T., and Yamamoto A. Modulation of intestinal P-glycoprotein function by Cremophor EL and other surfactants by an in vitro difusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci. 93 (2004) 877-885
27. Tanakaga H., Ohnishi A., Matsuo H., and Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefuit juice components in Caco-2 cells. Biol. Pharm. Bull. 21 (1998) 1062-1066
28. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41 (1981) 1967-1972
29. Tunblad K., Hammarlund-Udenaes M., and Jonsson E.N. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. Eur. J. Pharm. Sci. 24 (2005) 49-57
30. Valenzuela B., Nácher A., Casabó V.G., and Martín-Villodre A. The influence of active secretion processes on intestinal absorption of salbutamol sulphate in the rat. Eur. J. Pharm. Biopharm. 52 (2001) 31-37
31. Valenzuela, B., 2003. Absorción del salbutamol sulphate: Estudios "in situ" e "in vivo". Influencia de los procesos de secreción. Ph.D. Thesis, University of Valencia, Spain.
32. Valenzuela B., Nácher A., Ruiz-Carretero P., Martín-Villodre A., López-Carballo G., and Barettino D. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol sulphate intestinal absorption process. J. Pharm. Sci. 93 (2004) 1641-1648
33. Varma M.V.S., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48 (2003) 347-359
34. Vasilyeva E., and Forgac M. Interaction of the clathrin-coated vesicle V-ATPase with ADP and sodium azide. J. Biol. Chem. 273 (1998) 23823-23829
35. Williams P.J., and Ette E.I. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for industry: population pharmacokinetics'. Clin. Pharmacokinet. 39 (2000) 385-395
36. Woodland C., Koren G., Wainer I.W., Batist G., and Ito S. Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. Can. J. Physiol. Pharmacol. 81 (2003) 800-805